Figure 1. ITGB4-DC vaccine primes ITGB4-specific T cells in vivo, leading to killing of ITGB4 expressing cancer stem cells and differentiated tumor cells which is augmented by anti-PD-L1 administration.
Murine bone marrow derived DCs were isolated and expanded with GM-CSF and 2-mercaptoethanol. Approximately 1 × 106 activated DCs were cultured with 20 μg of ITGB4 protein overnight to generate ITGB4-DC vaccines. Each vaccine dose contained 2 × 106 ITGB4 pulsed DCs and was delivered subcutaneously.